Navigation Links
R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
Date:8/24/2009

TOKYO, Aug. 25 /PRNewswire/ -- We are pleased to announce that subject enrollment for the phase 2 clinical study of 0.15% UF-021 (generic name; isopropyl unoprostone; active ingredient of Rescula(R) eye-drops) in patients with retinitis pigmentosa has been completed.

We submitted the notification of the clinical trial in August 2008. Enrollment in the phase 2 study began at six clinical sites in late December 2008 and was completed on August 3, 2009.

The clinical study has progressed with no delay, no serious adverse effects, and only a few cases of discontinuation so far. Hereafter, we expect to complete the study by next spring, including data collection and analysis.

Retinitis pigmentosa is a progressive hereditary disease affecting nearly 50,000 people in Japan, which is characterized by night blindness. Patients generally suffer from peripheral visual field loss and low vision in the late stage of the disease. At present, there is no effective treatment for this disease.

We developed and launched isopropyl unoprostone eye-drops on the market as a drug for glaucoma and ocular hypertension in 1994. In recent studies on isopropyl unoprostone, the drug has been reported to present neuroprotective effects and a function to improve ocular circulation. Studies at some university hospitals have also suggested that isopropyl unoprostone eye-drops improve symptoms of retinitis pigmentosa or stop the progression of the disease.

We expect isopropyl unoprostone to become a unique drug for improvement of the quality of vision in patients with retinitis pigmentosa.

About R-Tech Ueno, Ltd.

R-Tech Ueno was established in September 1989 for the purpose of marketing and R&D of drugs. Under the leadership of the president, also a medical doctor, the company is developing new drugs on the theme "Physician-Oriented New Drug Innov
'/>"/>

SOURCE R-Tech Ueno, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
2. ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology
3. SIRO Clinpharm Completes Successful Implementation of Oracle Life Sciences Application Suite
4. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
5. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
6. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
7. Potentia Pharmaceuticals POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II
8. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
9. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
10. Major Restless Legs Study Completes Enrollment With Support From MediciGlobal
11. QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... SAN FRANCISCO, Calif. , Aug. 28, 2015 /PRNewswire/ ... for the treatment of cancer, today announced the filing ... U.S. Securities and Exchange Commission (SEC) relating to a ... number of shares to be offered and the price ... CytomX intends to list its common stock under the ...
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on China,s ... Developed by Roche under the trade name of ... the world. In Feb.26, 2010, it was approved by ... available in China all come ...
(Date:8/28/2015)... , Aug. 28, 2015  Today, in final ... (CDC) Contact Lens Health Week, 1-800 Contacts is sharing ... found that contact lens wearers who do not properly ... risk for eye infections. Most contact ... lenses, but a clean lens case is sometimes overlooked.  ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Bevacizumab Market 2015-2019 21-800 Contacts Shares Tips on How to Clean Lens Cases 2
... WESTON, Fla., Jan. 14, 2011 American Scientific ... (Pink Sheets: ASFX ) wishes to announces that ... is available at www.sec.gov , has been declared effective ... Registration Statement means that the Company will commence reporting of ...
... Research Institute (IDRI) today announced it has received a ... Foundation for "Chemical genomics for the identification of targets ... is to identify new leads and new drug targets ... of producing new drugs to treat tuberculosis (TB). The ...
Cached Medicine Technology:American Scientific Resources, Inc. Announces S-1 Registration Statement Effective; Commences Public Reporting Requirements 2IDRI Awarded Grant from Bill and Melinda Gates Foundation to Identify Candidates for Novel TB Drugs 2
(Date:8/29/2015)... ... August 29, 2015 , ... "I ... from Miller Place, N.Y. "I specialize in manual therapy, and my invention will ... can be used for additional muscle dysfunction throughout the body." , They developed ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... Next weekend ... of summer (which astronomically, officially ends on September 22nd this year). For IT security ... security hangovers linger on which could prove far more costly than a simple headache. ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health ... and sell Arterosil and Arterosil HP, and that all claims and counterclaims have ... Health Sciences, LLC (VHS) in the United States District Court for the Southern ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of ... for the position they are applying for, they are unable to pass the initial ... considering altering drug testing policies in order to be able to hire long-term, skilled ...
(Date:8/28/2015)... ... ... As reported by Medical Daily on August 22 , Cellfina, a non-invasive ... two years, the longest of any cellulite reduction system currently on the market. ... solution for their cellulite, according to Dr. Robert Weiss, director of the premier MD ...
Breaking Medicine News(10 mins):Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3
... survey of businesses that looks at their preparations for ... Health (HSPH) researchers found that only one-third believe they ... half their workforce were absent for two weeks due ... believe they could avoid such problems for one month ...
... In a new report, University of Illinois professor Barbara H. Fiese ... promote family mealtimes as a matter of public policy. "There ... protecting their families as taking 18 to 20 minutes to eat ... week," said Fiese, a U of I professor of human development ...
... WASHINGTON, Sept. 9 The Henry M. Jackson Foundation ... Tug McGraw Foundation (TMF) and Grammy Award-winning country music stars Tim ... from the Frontlines to the Homefront ." The presenting sponsor of ... Country United is a two-day event dedicated to supporting ...
... , BOSTON, Sept. 9 A recent study ... of laboratory use and confinement. Developmental Context Effects on ... the September issue, Vol. 45 (5), of the American Psychological ... , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090909/DC72238 ) , ...
... , , , ... the global anti-aging skincare market approached $15 billion(1), with 32 ... many over-the-counter products are claiming to achieve comparable benefits as ... to grow, but FDA-approved prescription products with rigorous efficacy and ...
... Workforce Prescriptions ("WRX") announced on Tuesday the launch of the Paradigm ... by a private endowment, developed to honor hospitals that have gone ... without resorting to workforce reductions or dramatic top-down mandates. , ... the paradigm shift in understanding required to see that the number ...
Cached Medicine News:Health News:Four-fifths of businesses foresee problems maintaining operations if H1N1 flu outbreak 2Health News:Four-fifths of businesses foresee problems maintaining operations if H1N1 flu outbreak 3Health News:Four-fifths of businesses foresee problems maintaining operations if H1N1 flu outbreak 4Health News:U of I acientist: Public policy should promote family mealtimes 2Health News:U of I acientist: Public policy should promote family mealtimes 3Health News:Tim McGraw and Faith Hill Lead Country United Effort to Benefit Military Medicine 2Health News:Tim McGraw and Faith Hill Lead Country United Effort to Benefit Military Medicine 3Health News:Chimpanzees Suffer Psychologically Like Humans 2Health News:Chimpanzees Suffer Psychologically Like Humans 3Health News:Leading Anti-Aging Prescription RENOVA(R) Continues To Deliver Maximum Results 2Health News:Leading Anti-Aging Prescription RENOVA(R) Continues To Deliver Maximum Results 3Health News:WRX Launches National Labor Efficiency Quality Award 2Health News:WRX Launches National Labor Efficiency Quality Award 3
Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 130o....
Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 110o. Most popular size or model....
25 gauge cannula. 2 mm vertical spatula tip with opening on right side. 10 mm from tip to bend. Polished finish....
Angled blade and flat serrated handle with polished finish. Blade: 1 mm x 10 mm....
Medicine Products: